Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Phase 1 study of GDC-0134, a dual leucine zipper kinase inhibitor, in ALS.
Katz JS, Rothstein JD, Cudkowicz ME, Genge A, Oskarsson B, Hains AB, Chen C, Galanter J, Burgess BL, Cho W, Kerchner GA, Yeh FL, Ghosh AS, Cheeti S, Brooks L, Honigberg L, Couch JA, Rothenberg ME, Brunstein F, Sharma KR, van den Berg L, Berry JD, Glass JD. Katz JS, et al. Among authors: galanter j. Ann Clin Transl Neurol. 2022 Jan;9(1):50-66. doi: 10.1002/acn3.51491. Epub 2022 Jan 10. Ann Clin Transl Neurol. 2022. PMID: 35014217 Free PMC article. Clinical Trial.
Phase I and scintigraphy studies to evaluate safety, tolerability, pharmacokinetics, and lung deposition of inhaled GDC-0214 in healthy volunteers.
Zhu R, Chen H, Galanter J, She G, Cai F, Durk MR, Zou Y, Chen L, Kenny JR, Vadhavkar S, Warren S, Taylor G, Hwang O, Eliahu A, Wynne C, Owen R. Zhu R, et al. Among authors: galanter j. Clin Transl Sci. 2022 May;15(5):1225-1237. doi: 10.1111/cts.13240. Epub 2022 Feb 26. Clin Transl Sci. 2022. PMID: 35157370 Free PMC article. Clinical Trial.
Dose-dependent inactivation of airway tryptase with a novel dissociating anti-tryptase antibody (MTPS9579A) in healthy participants: A randomized trial.
Rymut SM, Sukumaran S, Sperinde G, Bremer M, Galanter J, Yoshida K, Smith J, Banerjee P, Sverkos V, Cai F, Steffen V, Henderson LM, Rhee H, Belloni PN, Lin JH, Staton TL. Rymut SM, et al. Among authors: galanter j. Clin Transl Sci. 2022 Feb;15(2):451-463. doi: 10.1111/cts.13163. Epub 2021 Sep 30. Clin Transl Sci. 2022. PMID: 34581002 Free PMC article. Clinical Trial.
Inhaled JAK inhibitor GDC-0214 reduces exhaled nitric oxide in patients with mild asthma: A randomized, controlled, proof-of-activity trial.
Braithwaite IE, Cai F, Tom JA, Galanter JM, Owen RP, Zhu R, Williams M, McGregor AG, Eliahu A, Durk MR, Dengler HS, Zak M, Kenny JR, Wilson ME, Beasley R, Chen H. Braithwaite IE, et al. Among authors: galanter jm. J Allergy Clin Immunol. 2021 Sep;148(3):783-789. doi: 10.1016/j.jaci.2021.02.042. Epub 2021 Mar 17. J Allergy Clin Immunol. 2021. PMID: 33744327 Free article. Clinical Trial.
Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial.
Isenberg D, Furie R, Jones NS, Guibord P, Galanter J, Lee C, McGregor A, Toth B, Rae J, Hwang O, Desai R, Lokku A, Ramamoorthi N, Hackney JA, Miranda P, de Souza VA, Jaller-Raad JJ, Maura Fernandes A, Garcia Salinas R, Chinn LW, Townsend MJ, Morimoto AM, Tuckwell K. Isenberg D, et al. Among authors: galanter j. Arthritis Rheumatol. 2021 Oct;73(10):1835-1846. doi: 10.1002/art.41811. Epub 2021 Aug 24. Arthritis Rheumatol. 2021. PMID: 34042314 Clinical Trial.
Effects of inhaled JAK inhibitor GDC-4379 on exhaled nitric oxide and peripheral biomarkers of inflammation.
Chen H, Kunder R, Zou Y, Staton T, Zhu R, Galanter J, Gugelmann H, Owen R, Grimbaldeston MA, Chang JK, Durk MR, Eliahu A, Wilson MS, Choy DF, Wilson M, Black M, Doppen M, Kung S, Oldfield K, Sparks J, Beasley R, Braithwaite I. Chen H, et al. Among authors: galanter j. Pulm Pharmacol Ther. 2022 Aug;75:102133. doi: 10.1016/j.pupt.2022.102133. Epub 2022 May 26. Pulm Pharmacol Ther. 2022. PMID: 35644305 Clinical Trial.
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of MHAA4549A, a Monoclonal Antibody, plus Oseltamivir in Patients Hospitalized with Severe Influenza A Virus Infection.
Lim JJ, Nilsson AC, Silverman M, Assy N, Kulkarni P, McBride JM, Deng R, Li C, Yang X, Nguyen A, Horn P, Maia M, Castro A, Peck MC, Galanter J, Chu T, Newton EM, Tavel JA. Lim JJ, et al. Among authors: galanter j. Antimicrob Agents Chemother. 2020 Jun 23;64(7):e00352-20. doi: 10.1128/AAC.00352-20. Print 2020 Jun 23. Antimicrob Agents Chemother. 2020. PMID: 32393496 Free PMC article. Clinical Trial.
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of the Monoclonal Antibody MHAA4549A in Patients With Acute Uncomplicated Influenza A Infection.
Lim JJ, Dar S, Venter D, Horcajada JP, Kulkarni P, Nguyen A, McBride JM, Deng R, Galanter J, Chu T, Newton EM, Tavel JA, Peck MC. Lim JJ, et al. Among authors: galanter j. Open Forum Infect Dis. 2021 Dec 10;9(2):ofab630. doi: 10.1093/ofid/ofab630. eCollection 2022 Feb. Open Forum Infect Dis. 2021. PMID: 35106315 Free PMC article.
53 results